Rational pharmacotherapy in early psychosis

British Journal of Psychiatry

Volumn 187, Issue SUPPL. 48, 2005, Pages

  Remington, Gary ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; REMOXIPRIDE; RISPERIDONE; THIORIDAZINE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITIVE THERAPY; CONFERENCE PAPER; DECISION MAKING; DRUG EFFICACY; EDUCATION PROGRAM; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE INTOLERANCE; HIGH RISK POPULATION; HUMAN; ORTHOSTATIC HYPOTENSION; PSYCHOSIS; QT PROLONGATION; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WEIGHT GAIN; ARTICLE; PATIENT CARE; PRACTICE GUIDELINE; TIME;

ANTIPSYCHOTIC AGENTS; EPISODE OF CARE; HUMANS; PRACTICE GUIDELINES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TIME FACTORS;

EID: 23744460287     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.187.48.s77     Document Type: Conference Paper

References (113)

1. Addington, J., Mansley, C. & Addington, D. (2003) Weight gain in first-episode psychosis. Canadian Journal of Psychiatry, 48, 272-276.
2. Aguilar, E. J., Keshavan, M. S., Martinez-Quiles, M. D., et al. (1994) Predictors of acute dystonia in first-episode psychotic patients. American Journal of Psychiatry, 151, 1819-1821.
3. Allebeck, P. & Wistedt, B. (1986) Mortality in schizophrenia. A ten-year follow-up based on the Stockholm County inpatient register. Archives of General Psychiatry, 43, 650-653.
4. Allison, D. B. & Casey, D. E. (2001) Antipsychotic-induced weight gain: a review of the literature. Journal of Clinical Psychiatry, 62, 22-31.
5. Allison, D. B., Mentore, J. L., Heo, M., et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry, 156, 1686-1696.
6. Andersson, C., Hamer, R. M., Lawler, C. P., et al. (2002) Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacology, 27, 143-151.
7. Baldessarini, R. J., Katz, B. & Cotton, P. (1984) Dissimilar dosing with high-potency and low-potency neuroleptics. American Journal of Psychiatry, 141, 748-752.
8. Baldessarini, R. J., Cohen, B. M. & Teicher, M. H. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45, 79-91.
9. Baptista, T. (2002) Atypical antipsychotic drugs and glucose dysregulation. Canadian Journal of Psychiatry, 47, 94-96.
10. Beasley, C. M., Dellva, M. A., Tamura, R. N., et al. (1999) Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. British Journal of Psychiatry, 174, 23-30.
11. Bollini, P., Pampallona, S., Orza, M. J., et al. (1994) Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychological Medicine, 24, 307-316.
12. Brenner, H. D., Dencker, S. J., Goldstein, M. J., et al. (1990) Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin, 16, 551-561.
13. Brown, S., Inskip, H. & Barraclough, B. (2000) Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212-217.
14. Buckley, P. F. (1999) New antipsychotic agents: emerging clinical profiles. Journal of Clinical Psychiatry, 60, 12-17.
15. Cannon, T. D., Huttunen, M. O., Dahlstrom, M., et al. (2002) Antipsychotic drug treatment in the prodromal phase of schizophrenia. American Journal of Psychiatry, 159, 1230-1232.
16. Carpenter, W. T. Jr (2001) Evidence-based treatment for first-episode schizophrenia? American Journal of Psychiatry, 158, 1771-1773.
17. Carpenter, W. T. Jr & Gold, J. M. (2002) Another view of therapy for cognition in schizophrenia. Biological Psychiatry, 51, 969-971.
18. Casey, D. E. (1996) Side effect profiles of new antipsychotic agents. Journal of Clinical Psychiatry, 57, 40-45.
19. Censits, D. M., Ragland, J. D., Gur, R. C., et al. (1997) Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophrenia Research, 24, 289-298.
20. Chakos, M. H., Lieberman, J. A., Alvir, J., et al. (1995) Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet, 345, 456-457.
21. 2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biological Psychiatry, 29, 629-634.
22. Cornblatt, B., Lencz, T., Correll, C., et al. (2002) Treating the prodrome: naturalistic findings from the RAP program. Acta Psychiatrica Scandinavica, 106, 44.
23. Craig, T. J., Bromet, E. J., Fennig, S., et al. (2000) Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? American Journal of Psychiatry, 157, 60-66.
24. Creese, I., Burt, D. R. & Snyder, S. H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192, 481-483.
25. Crow, T. J., MacMillan, J. F., Johnson, A. L., et al. (1986) A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry, 148, 120-127.
26. Cunningham Owens, D. (1996) Adverse effects of antipsychotic agents: do newer agents offer advantages? Drugs, 51, 895-930.
27. Dolder, C. R. & Jeste, D. V. (2003) Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biological Psychiatry, 53, 1142-1145.
28. Emsley, R. A. & The Risperidone Working Group (1999) Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophrenia Bulletin, 25, 721-729.
29. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Archives of General Psychiatry, 49, 538-544.
30. Felker, B., Yazel, J. J. & Short, D. (1996) Mortality and medical comorbidity among psychiatric patients: a review. Psychiatric Services, 47, 1356-1363.
31. Finlay, J. M. (2001) Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities. Schizophrenia Bulletin, 27, 431-442.
32. Fleischhacker, W. W. & Hummer, M. (1997) Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs, 53, 915-929.
33. Frances, A., Docherty, J. P. & Kahn, D. A. (1998) Treatment of schizophrenia. The Expert Consensus Guideline Series. Journal of Clinical Psychiatry, 57 (suppl. 12B), s1-s57.
34. Geddes, J., Freemantle, N., Harrison, P., et al. (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ, 321, 1371-1376.
35. Gitlin, M., Nuechterlein, K., Subotnik, K. L., et al. (2001) Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. American Journal of Psychiatry, 158, 1835-1842.
36. Glassman, A. H. & Bigger, J.T. Jr (2001) Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. American Journal of Psychiatry, 158, 1774-1782.
37. Glazer, W. M., Morgenstern, H. & Doucette, J. T. (1993) Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. Journal of Clinical Psychiatry, 54, 133-139.
38. Haas, G. L. & Sweeney, J. A. (1992) Premorbid and onset features of first-episode schizophrenia. Schizophrenia Bulletin, 18, 373-386.
39. Hafner, H. & an der Heiden, W. (1997) Epidemiology of schizophrenia. Canadian Journal of Psychiatry, 42, 139-151.
40. Henderson, D. C. (2002) Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs, 16, 77-89.
41. Ho, B. C., Andreasen, N. C., Flaum, M., et al. (2000) Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. American Journal of Psychiatry, 157, 808-815.
42. Ho., B. C., Alicata, D., Ward, J., et al. (2003) Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. American Journal of Psychiatry, 160, 142-148.
43. Hoff, A. L., Sakuma, M., Razi, K., et al. (2000) Lack of association between duration of untreated illness and severity of cognitive and structural brain deficits at the first episode of schizophrenia. American Journal of Psychiatry, 157, 1824-1828.
44. Jeste, D. V., Lacro, J. P., Bailey, A., et al. (1999a) Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. Journal of the American Geriatric Society, 47, 716-719.
45. Jeste, D. V., Lacro, J. P., Palmer, B., et al. (1999b) Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. American Journal of Psychiatry, 156, 309-311.
46. Jeste, D. V., Okamoto, A., Napolitano, J., et al. (2000) Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. American Journal of Psychiatry, 157, 1150-1155.
47. Kane, J. M., Rifkin, A., Quitkin, F., et al. (1982) Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Archives of General Psychiatry, 39, 70-73.
48. Kapur, S. & Remington, G. (2000) Atypical antipsychotics. BMJ, 321, 1360-1361.
49. 2 receptors. Implications for atypical antipsychotic action. Journal of Psychiatry & Neuroscience, 25, 161-166.
50. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. American Journal of Psychiatry, 153, 948-950.
51. 2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology, 131, 148-152.
52. 2 occupancy predict antipsychotic response and side effects? A randomised double-blind test of the hypothesis. Schizophrenia Research, 36, 242.
53. Kissling, W. E. (1991) Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Bertin: Springer.
54. 2 antagonists. Human Psychopharmacology, 10, 455-460.
55. Leucht, S., Ptachel-Walz, G., Abraham, D., et al. (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research, 35, 51-68.
56. Lieberman, J., Jody, D., Geisler, S., et al. (1993) Time course and biologic correlates of treatment response in first-episode schizophrenia. Archives of General Psychiatry, 50, 369-376.
57. Lieberman, J. A. (1999) Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biological Psychiatry, 46, 729-739.
58. Lieberman, J. A., Koreen, A. R., Chakos, M., et al. (1996) Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Journal of Clinical Psychiatry, 57, 5-9.
59. Lieberman, J. A., Phillips, M., Gu, H., et al. (2003) Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology, 28, 995-1003.
60. Lindenmayer, J. P., Czobor, P., Volavka, J., et al. (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychiatry, 160, 290-296.
61. Loebel, A. D., Lieberman, J. A., Alvir, J. M., et al. (1992) Duration of psychosis and outcome in first-episode schizophrenia. American Journal of Psychiatry, 149, 1183-1188.
62. McEvoy, J. P. (1986) The neuroleptic threshold as a marker of minimum effective neuroleptic dose. Comprehensive Psychiatry, 27, 327-335.
63. McEvoy, J. P., Hogarty, G. E. & Steingard, S. (1991) Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry, 48, 739-745.
64. McGorry, P. D., Phillips, L. J., Yung, A. R., et al. (2000) A randomised controlled trial of interventions in the pre-psychotic phase of psychotic disorders. Schizophrenia Research, 41, 9.
65. McGorry, P. D., Harrigan, S. M., Amminger, P., et al. (2001) Untreated initial psychosis. American Journal of Psychiatry. 158, 1161-1163.
66. Meltzer, H. Y. (1989) Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Archives of General Psychiatry, 46, 672.
67. Meyer, J. M. (2001) Novel antipsychotics and severe hyperlipidemia. Journal of Clinical Psychopharmacology, 21, 369-374.
68. Mir, S. & Taylor, D. (2001) Atypical antipsychotics and hyperglycaemia. International Clinical Psychopharmacology, 16, 63-73.
69. Mojtabai, R., Lavelle, J., Gibson, P. J., et al. (2002) Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatric Services, 53, 337-339.
70. Morgenstern, H. & Glazer, W. M. (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Archives of General Psychiatry, 50, 723-733.
71. Mortensen, P. B. & Juel, K. (1993) Mortality and causes of death in first admitted schizophrenic patients. British Journal of Psychiatry, 163, 183-189.
72. Nasrallah, H. (2003) A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology, 28 (suppl. I), s83-s96.
73. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biological Psychiatry, 33, 227-235.
74. Oosthuizen, P., Emsley, R. A., Maritz, J. S., et al. (2003) Treatment with low-dose haloperidol does not protect against tardive dyskinesia. Schizophrenia Research, 60 (suppl.) s364.
75. Osby, U., Correia, N., Brandt, L., et al. (2000) Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophrenia Research, 45, 21-28.
76. Peacock, L., Solgaard, T., Lublin, H., et al. (1996) Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology, 124, 188-196.
77. Pelosi, A. J. & Birchwood, M. (2003) Is early intervention for psychosis a waste of valuable resources? British Journal of Psychiatry, 182, 196-198.
78. 123I]IBZM SPET study. Psychological Medicine, 23, 791-797.
79. Remington, G. (2003) Understanding antipsychotic atypicality': a clinical and pharmacological moving target. Journal of Psychiatry & Neuroscience, 28, 275-284.
80. Remington, G. & Kapur, S. (2000) Atypical antipsychotics: are some more atypical than others? Psychopharmacology, 148, 3-15.
81. Remington, G., Kapur, S. & Zipursky, R. B. (1998) Pharmacotherapy of first-episode schizophrenia. British Journal of Psychiatry, 172 (suppl. 33), 66-70.
82. Remington, G., Kapur, S. & Zipursky, R. B. (2000) Antipsychotic use in first-episode psychosis. Primary Psychiatry, 7, 58-62.
83. Remington, G., Kapur, S., Zipursky, R. B. (2001a) Pharmacotherapy of first episode psychosis. In Early Intervention In Psychotic Disorders (eds T. Miller, A. Sarnoff, T. H. McGlashan, J. Libiger & J. O. Johannessen), pp. 167-180. London: Kluwer.
84. Remington, G. J., Kapur, S., Shammi, C., et al. (2001b) 'Extended' dosing as an alternative to 'intermittent' or 'targeted' antipsychotic therapy: rationale and pilot study. Schizophrenia Research, 49, 243.
85. Robinson, D. G., Woerner, M. G., Alvir, J. M., et al. (1999a) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241-247.
86. Robinson, D. G., Woerner, M. G., Alvir, J. M., et al. (1999b) Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 156, 544-549.
87. Robinson, D. G., Woerner, M. G. & McMeniman, M. (2003) Recovery in first episode schizophrenia. Schizophrenia Research, 60 (suppl.), s301.
88. Sanger, T. M., Lieberman, J. A., Tohen, M., et al. (1999) Olanzapine versus haloperidol treatment in first-episode psychosis. American Journal of Psychiatry, 156, 79-87.
89. 2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia. Biological Psychiatry, 43, 660-665.
90. Scully, P. J., Coakley, G., Kinsella, A., et al. (1997) Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia. Psychological Medicine, 27, 1303-1310.
91. Seeman, P., Bzowej, N. H., Guan, H. C., et al. (1987) Human brain dopamine receptors in children and aging adults. Synapse, 1, 399-404.
92. 2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. American Journal of Psychiatry, 156, 876-884.
93. Seeman, P., Lee, T., Chau-Wong, M., et al. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature, 261, 717-719.
94. 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology, 152, 174-180.
95. Smith, R. C., Chua, J. W., Lipetsker, B., et al. (1996) Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. Journal of Clinical Psychiatry, 57, 460-466.
96. Stip, E. (2000) Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics. Journal of Psychiatry & Neuroscience, 25, 137-153.
97. Tamminga, C. A. (1997) The promise of new drugs for schizophrenia treatment. Canadian Journal of Psychiatry, 42, 265-273.
98. Taylor, D. M. (2003) Antipsychotics and QT prolongation. Acta Psychiatrica Scandinavica, 107, 85-95.
99. Tohen, M., Stoll, A. L., Strakowski, S. M., et al. (1992) The McLean First-Episode Psychosis Project: six-month recovery and recurrence outcome. Schizophrenia Bulletin, 18, 273-282.
100. Tollefson, G. D., Beasley, C. M., Jr., Tamura, R. N., et al. (1997) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry, 154, 1248-1254.
101. Umbricht, D. & Kane, J. M. (1996) Medical complications of new antipsychotic drugs. Schizophrenia Bulletin, 22, 475-483.
102. Waddington, J. L. & O'Callaghan, E. (1997) What makes an antipsychotic 'atypical'? CNS Drugs, 7, 341-346.
103. Weinberger, D. R. (2002) Schizophrenia, the prefrontal cortex, and a mechanism of genetic susceptibility. European Psychiatry, 17 (suppl. 4), s355-s362.
104. Wilson, W. H. (1996) Time required for initial improvement during clozapine treatment of refractory schizophrenia. American Journal of Psychiatry, 153, 951-952.
105. Wirshing, D. A., Spellberg, B. J., Erhart, S. M., et al. (1998) Novel antipsychotics and new onset diabetes. Biological Psychiatry, 44, 778-783.
106. Wirshing, D. A., Wirshing, W. C., Kysar, L., et al. (1999) Novel antipsychotics: comparison of weight gain liabilities. Journal of Clinical Psychiatry, 60, 358-363.
107. Wirshing, D. A., Boyd, J. A., Meng, L. R., et al. (2002) The effects of novel antipsychotics on glucose and lipid levels. Journal of Clinical Psychiatry, 63, 856-865.
108. Woerner, M. G., Alvir, J. M., Saltz, B. L., et al. (1998) Prospective study of tardive dyskinesia in the elderly: rates and risk factors. American Journal of Psychiatry, 155, 1521-1528.
109. Wolkin, A., Barouche, F., Wolf, A. P., et al. (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. American Journal of Psychiatry, 146, 905-908.
110. Woods, S., Brier, A., Zipursky, R., et al. (2003) Randomized trial of olanzapine versus placebo in the symptomatic treatment of the schizophrenic prodrome. Biological Psychiatry, 54, 453-464.
111. Wyatt, R. J. (1995) Early intervention for schizophrenia: can the course of the illness be altered? Biological Psychiatry, 38, 1-3.
112. Wyatt, R. J., Green, M. F. & Tuma, A. H. (1997) Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychological Medicine, 27, 261-268.
113. Zhang-Wong, J., Zipursky, R. B., Beiser, M., et al. (1999) Optimal haloperidol dosage in first-episode psychosis. Canadian Journal of Psychiatry, 44, 164-167.